Inhibitory KIR ligands are associated with higher *P. falciparum* parasite prevalence

Jean C. Digitale*[1,2], Perri C. Callaway*[1,3], Maureen Martin[4], George Nelson[5], Mathias Viard[4], John Rek[6], Emmanuel Arinaitwe[6,7], Grant Dorsey[1], Moses Kamya[6,8], Mary Carrington[4,9], Isabel Rodriguez-Barraquer[†1], Margaret E. Feeney[†1,10]

*,[†]These authors contributed equally

[1]Department of Medicine, University of California San Francisco, San Francisco, CA, USA

[2]Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA

[3]Infectious Disease and Immunity Graduate Group, University of California Berkeley, Berkeley, CA, USA

[4]Basic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA

[5]Advanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD

[6]Infectious Diseases Research Collaboration, Kampala, Uganda

[7] London School of Hygiene and Tropical Medicine, London, United Kingdom

[8]Department of Medicine, Makerere University, Kampala, Uganda

[9]Ragon Institute of MGH MIT and Harvard, Cambridge, MA, USA

[10]Department of Pediatrics, University of California San Francisco, San Francisco, CA, USA

Correspondence: Margaret Feeney, 1001 Potrero Avenue, Building 3, Room 545a, San Francisco CA 94110, phone: (628) 206-8218, email: Margaret.feeney@ucsf.edu

The authors have declared that no conflict of interest exists.

Abstract

Killer cell immunoglobulin-like receptors (KIR) and their HLA ligands influence the outcome of many infectious diseases. Data from a longitudinal cohort comprised of three study sites in Uganda with varying malaria transmission intensity show that presence of the HLA-C2 and HLA-Bw4 ligands for inhibitory KIR2DL1 and KIR3DL1, respectively, increase the likelihood of *Plasmodium falciparum (Pf)* parasitemia in an additive manner. For KIR2DL1/2/3, parasite prevalence was highest among individuals with KIR/HLA-C ligand pairs that are capable of the greatest cellular inhibition. Individuals homozygous for HLA-C2, which mediates strong inhibition via the near ubiquitous KIR2DL1 receptor, had the highest odds of parasitemia, while HLAC1/C2 heterozygotes had intermediate odds, and individuals homozygous for HLA-C1, which mediates weaker inhibition through KIR2DL2/3, had the lowest odds of parasitemia. A higher risk of parasitemia was also observed in the pairing of HLA-C1 with its receptor KIR2DL2 compared to its less inhibitory receptor KIR2DL3. Additionally, higher surface expression of HLA-C, the ligand for KIR2DL1/2/3, was associated with a higher likelihood of parasitemia. Together these data indicate that stronger KIR-mediated inhibition confers a higher risk of *Pf* parasitemia and suggest that KIR-expressing effector cells play a role in mediating anti-parasite immunity.

Introduction

Killer cell immunoglobulin-like receptors (KIR) are a family of 14 transmembrane receptors that are expressed on natural killer (NK) cells, gamma delta T cells, and some CD8 T cells whose known ligands are primarily HLA class I molecules. While some KIR genes are considered framework and are universal, other KIR genes are expressed by only a subset of individuals(1). At the cellular level, KIRs are stochastically expressed with only a fraction of KIR expressing cells expressing a given KIR from the individual's genotype(2). Interactions of KIR with their HLA ligands have been shown to govern the outcome of several, predominantly viral, infections (3–5). Because the KIR and HLA loci are on different chromosomes and they segregate independently, associations of the KIR-HLA compound genotype with susceptibility to a particular pathogen can shed light on the mechanisms critical for immunity and immunopathogenesis.

Plasmodium falciparum (Pf) malaria has caused hundreds of millions of deaths throughout history and continues to kill nearly half of a million people each year(6). As a result, malaria has exerted strong selective pressure on human evolution(7). Most genetic determinants of malaria susceptibility identified to date result in erythrocyte defects or cytoadhesion variants. However, a recent GWAS analysis of 17,000 individuals estimated that known variants account for only 11% of the total genetic influence on malaria susceptibility(8). Notably, most studies of host genetic susceptibility to malaria, including the GWAS study noted above, have involved comparison of severe malaria cases to controls with non-severe (but symptomatic) malaria (9, 10). This analytic framework could overlook genes that influence protection at the earlier pre-erythrocytic stages of the *Pf* life cycle, before blood stage infection is established. Additionally, genetic factors

governing inflammation as well as non-genetic factors (socio-economic status, access to care) likely influence the development of severe malaria. Thus, comparison of severe vs non-severe malaria may fail to identify host genetic factors governing susceptibility to malaria infection.

Although children residing in malaria-endemic regions experience an age-related decline in symptomatic malaria (termed "clinical immunity"), such individuals remain susceptible to asymptomatic blood stage *Pf* infections throughout life. Studies of naturally exposed populations have found no evidence that sterilizing immunity is acquired with age (11). In contrast, experimental vaccination strategies such as sporozoite inoculation have been shown to induce sterile protection at the liver stage (termed "pre-erythrocytic immunity"), which prevents or greatly limits the establishment of blood-stage parasitemia(12, 13). Pre-erythrocytic immunity is believed to be mediated by the cellular immune response, including CD8 T cells(14, 15), NK (16–18) cells and the semi-innate Vδ2Vγ9 subset of γδ T cells (19–22). Hence, it is likely that the immune mechanisms that influence sterile protection and restriction of parasite replication differ from those that mediate clinical immunity, with the latter involving immunoregulatory processes that dampen the inflammation responsible for fever and other symptoms, while fostering successful long-term parasitism.

To date, the association of KIR and their HLA ligands with susceptibility to malaria has been examined in very few studies and almost entirely in the context of case-control comparisons of severe vs. non-severe malaria(9, 10). Here, we examined the influence of well-defined KIR-HLA ligand pairs on the prevalence of *Pf* parasitemia and malaria in a large longitudinal cohort of individuals from three sites with varying malaria transmission in Uganda to determine the

influence of KIR on susceptibility to *Pf* infection. This analysis revealed that more inhibitory KIR-HLA pairs were associated with a higher odds of parasitemia, supporting a role for cellular immunity in host restriction of the parasite.

Results and Discussion

We analyzed data from 890 individuals (657 children and 233 adults) recruited from 292 households, who were followed longitudinally at 3 study sites in Uganda (Table 1). Blood smears were performed every 3 months to assess *Pf* parasitemia. Reflecting the varying transmission intensity among the sites, the prevalence of parasitemia was highest among children in Tororo (64%), followed by Kanungu (36%) and Jinja (13%). The incidence of malaria, defined as parasitemia accompanied by fever, also differed among the three sites and was inversely associated with age (23). Both malaria incidence and parasite prevalence by microscopy were substantially lower among adults than children (Table 1).

Genotyping of KIR and HLA class I loci was performed (Table 2), and individuals were categorized based on the presence of well-characterized KIR ligand groups (i.e. HLA-C1 for KIR2DL1, HLA-C2 for KIR2DL2/3, and HLA-Bw4 for KIR3DL1). The prevalence of the inhibitory KIR genes KIR2DL1 and KIR3DL1 was very high (both >98.5%), consistent with previous reports in East African populations (24).

To assess whether KIR and HLA class I influence the risk of *Pf* infection, we tested associations of individual KIR genes, HLA ligand groups and KIR-HLA compound genotypes with 5 malaria outcome measures: the prevalence of parasitemia, clinical malaria incidence, parasite density (stratified by routine quarterly visits and malaria visits), the conditional probability of clinical malaria given the presence of parasitemia, and temperature at parasitemic visits, conditional on parasite density. There was no association between the presence of any KIR gene with any of the

outcomes (Supplemental Table 1).

Among the best characterized KIR-HLA ligand interactions are the inhibitory KIR2DL1 with the HLA-C2 subgroup of HLA-C alleles and KIR2DL2/L3 with the HLA-C1 subgroup. HLA-C2 alleles possess a lysine at amino acid position 80 whereas HLA-C1 alleles have an asparagine (25). Since KIR2DL1 and KIR2DL2/3 were both present in virtually all subjects (Table 2), the presence of their HLA ligand determines whether an individual has an inhibitory KIR/HLA-C pair. Further, within these inhibitory KIR/HLA-C ligand interactions, there is a hierarchy of inhibition. KIR2DL1/HLA-C2 provides the strongest inhibition, followed by KIR2DL2/HLA-C1, while KIR2DL3/HLA-C1 provides the weakest inhibition (26–28). We found that for those with at least one copy of the KIR2DL1 ligand HLA-C2, the odds of being parasitemic increased 1.31-fold (p=0.017, empirical p*=0.010, empirical false discovery rate q=0.047). Conversely, having at least one HLA-C1 allele decreased the odds of being parasitemic (OR=0.79, p=0.016, p*=0.013, q=0.051).

Next, we assessed the zygosity of HLA-C ligand groups to determine whether the number of copies of either HLA-C1 or HLA-C2 influenced parasite prevalence. HLA-C1/C1 individuals are only able to receive inhibitory signals via KIR2DL2/3, whereas HLA-C2/C2 individuals receive inhibitory signals predominantly via KIR2DL1, and heterozygous individuals have the ligand for all three of these KIRs(25). Comparison of these groups revealed a stepwise increase in parasite prevalence, with HLA-C2/C2 individuals having 1.54-fold higher odds of parasitemia compared to HLA-C1/C1 individuals (Table 3). Heterozygous (HLA-C1/C2) individuals had intermediate odds. These results suggest that engagement of KIR2DL1 with its ligand HLA-C2, the most

inhibitory of the KIR-HLA-C ligand pairs, increases parasite prevalence in comparison to engagement of KIR2DL2/3 with their ligand HLA-C1, which in general provide weaker inhibitory signals. KIR2DL1 expressing cells from C2/C2 homozygous individuals will receive stronger inhibitory signals, potentially dampening the effector cell response to *Pf* infection.

KIR2DL2 and KIR2DL3 segregate as alleles of the same locus, but KIR2DL2 provides stronger effector cell inhibition when bound to HLA-C1(26). Overall, no difference in parasitemia risk was observed between KIR2DL3/C1 and KIR2DL2/C1 individuals (Table 4). However, KIR2DL2 is in linkage disequilibrium with the homologous activating receptor KIR2DS2 (Wn*=0.85, Fisher's exact test p<0.001), which may be capable of binding HLA-C1 ligands in a peptide dependent manner (29, 30). To test whether KIR2DS2 may have an opposing effect that could obscure the stronger inhibitory impact of KIR2DL2, we examined the impact of KIR2DL2 and KIR2DL3 among individuals lacking the KIR2DS2 gene. This revealed that presence of at least one copy of KIR2DL2 increased the odds of being parasitemic 1.6-fold compared to those with only KIR2DL3 (Table 4). Again, consistent with the hierarchy of inhibition, we found that the KIR with stronger inhibitory potential increases parasite prevalence.

While the least inhibitory KIR-HLA combination in the hierarchy, KIR2DL3/HLA-C1, was associated with a lower prevalence of *Pf* infection, previous data suggest that it may increase the risk of inflammatory complications of malaria. Hirayasu et. al. reported that this KIR2DL3/HLA-C1 pairing is associated with the development of cerebral malaria (9). Immunopathology contributes substantially to the neurological damage caused by cerebral malaria(31) and NK cells have been found to accumulate in the brain microvasculature(32).

Lower KIR inhibition may allow unrestrained NK cell activation that could contribute to immune-mediate pathology in the brain. This would be consistent with the hypothesis that mechanisms that prevent initial *Pf* infection and those that prevent severe disease are distinct and may have a balancing effect on the maintenance of different KIR and HLA ligands in malaria endemic populations.

Another inhibitory receptor, KIR3DL1, recognizes a subset of HLA-A and HLA-B alleles that contain the HLA-Bw4 motif defined by amino acid residues 77-83 on the alpha1-helix(33). Similar to KIR2DL1, the KIR3DL1 gene was nearly universal in our cohort (98.7%), hence its effect on parasite prevalence could not be estimated directly. However, only 74.8% of individuals have an HLA-Bw4 ligand, enabling us to estimate the effect of the KIR-HLA ligand pair. Among individuals with the HLA-Bw4 ligand, the odds of parasitemia were 1.31-fold higher than in individuals lacking HLA-Bw4 (p=0.012, p*=0.006, q=0.040). This further supports the hypothesis that greater inhibition via KIR increases the likelihood of parasitemia, perhaps due to dampened cellular immunity.

Because both HLA-C2 and HLA-Bw4 were found to increase parasite prevalence and they have previously been shown to be in linkage disequilibrium, we looked for an additive effect of the two ligand groups by analyzing the combined genotype. Having both HLA-C2 and HLA-Bw4 increased the odds of being parasitemic by 1.46 times compared to HLA-C2 alone (p=0.001, p*<0.001, q=0.008) and by 1.51 times compared to HLA-Bw4 alone (p=0.002, p*=0.001, q=0.012). This suggests an additive inhibitory effect of the two KIR-HLA ligand pairs. Together,

this supports a model wherein the more inhibitory signals that KIR expressing effector cells receive, the greater the risk of parasitemia.

HLA-C molecules have been ascribed two distinct roles in cellular immunity – as ligands for inhibitory KIR, and as antigen presenting molecules for CD8 T cells – both of which have been shown to influence infectious disease outcomes (3, 5, 34). In contrast to HLA-A and -B molecules, surface expression of HLA-C is 10-15 fold lower and varies substantially amongst individual allotypes(35). During viral infections such as with HIV, HLA-C alleles that are more highly expressed at the cell surface have been associated with a more potent CD8 T cell response and enhanced viral control (36, 37). To further elucidate the means by which HLA-C influences *Pf* infection, we examined the relationship of HLA-C surface expression level to *Pf* parasite prevalence. We assigned each HLA-C allele a value based on its known expression levels as previously described (38) and calculated a total HLA-C expression level for each individual. In contrast to HIV infection, where highly expressed HLA-C allotypes are protective, we found that higher HLA-C expression was associated with an *increased* odds of *Pf* parasitemia (1.12-fold increase per one standard deviation of expression; p=0.014, p*=0.006, q=0.040). Thus, antigen presentation to T cells may not be the primary mechanism by which HLA-C influences restriction of *Pf*, but rather, higher HLA-C expression may lead to an increase in KIR-mediated inhibition of effector cells.

Finally, we examined the association of KIR-HLA ligand pairs with several other parasitological and clinical outcomes. We did not observe an association of KIR-HLA ligand pairings with clinical malaria (defined as fever plus parasitemia), parasite density (log parasitemia) given

parasitemia, odds of being symptomatic (febrile) given parasitemia, or temperature given

parasitemia (Supplemental Table 1b-f). Together these results are most consistent with an

influence of KIR-expressing effector cells on restriction of parasite replication, rather than on the

downstream inflammatory consequences that eventuate in fever and other clinical symptoms.

Furthermore, in our sensitivity analyses, when the definition of parasitemia was expanded to also

include submicroscopic *Pf* infections detectable by loop-mediated isothermal amplification (data

limited to children), similar associations for all results stated above were observed (Supplemental

Table 2). Results for models stratified by site (Supplemental Table 3a-c) or restricted to children

showed similar association as described above (Supplemental Table 4), as did models excluding

individuals with hemoglobin S (sickle cell) mutations (Supplemental Table 5).

The association of KIR-HLA compound genotypes with the prevalence of parasitemia is

somewhat paradoxical given that *Pf* spends most of its life cycle outside of HLA-expressing

cells. Following intradermal inoculation by mosquitoes, *Pf* sporozoites migrate via the dermis

and lymphatics to infect hepatocytes, the only stage in the parasite replicative life cycle in which

it is within an HLA-expressing host cell(39). Within the hepatocyte, parasites expand 2000-

40,000 fold, then emerge synchronously as merozoites, which establish a self-propagating cycle

of erythrocytic infection (40, 41). Because erythrocyte membranes contain little to no HLA (42),

we hypothesize that the influence of KIR on cell-mediated anti-parasite immunity may occur

primarily during the liver stage when the multiplicity of infection is lowest. It has previously

been shown that increasing KIR mediated NK cell inhibition is associated with poorer clearance

of HCV and HBV in the liver (3, 5). However, it is possible that the observed impacts of KIR-

HLA pairs on parasite prevalence may be due to enhanced spontaneous clearance of parasitemia rather than cessation of infection at the liver stage. During the blood stage, KIR-expressing effector cells may respond more strongly to an HLA-devoid cell due to the loss of tonic inhibitory signaling via inhibitory KIR (43). KIR inhibition may also influence the clearance of parasites through ADCC (44, 45). At either stage of infection, the observed genotypic differences in parasite prevalence may be mediated by NK cells, $\gamma\delta$ T cells or CD8 T cells, all of which can express KIR.

It is well established that KIRs influence the immune response to and ultimate outcome of numerous viral infections, but relatively few studies have investigated their role in the response to non-viral pathogens including parasites. Our finding that inhibitory KIR ligands increase the risk of *Pf* parasitemia indicates that the influence of KIR on host immunity extends to parasitic infections. Moreover, this association suggests that cellular immune responses play an important role in restricting *Pf* infection, perhaps during the earliest stages of infection, before blood-stage parasitemia is established. These findings represent a novel genetic determinant of malaria susceptibility and further our understanding of antimalarial immunity with implications for vaccine design.

Methods

Study approval

This study was granted ethical approval from the Makerere University School of Medicine Research and Ethics Committee, the London School of Hygiene and Tropical Medicine Ethics Committee, the University of California, San Francisco, Committee on Human Research and the Uganda National Council for Science and Technology. All participants and/or their parents/guardians gave written informed consent for their household upon enrollment.

Clinical and parasitological outcomes

Data were collected from Ugandan subjects enrolled into three parallel longitudinal cohorts conducted as part of the East Africa International Center of Excellence for Malaria Research, at sites with a range of malaria transmission intensity. Nagongera, in Tororo district, is a high-transmission, rural area in southeastern Uganda. Kihihi, in Kanungu district, is a rural area in southwestern Uganda with moderate transmission. Walukuba, in Jinja district, is a relatively low-transmission, peri-urban area near Lake Victoria. Households in the three sites were enumerated and approximately 100 households per site were randomly selected. All children aged 6 months to 10 years and one adult caregiver per household who met eligibility criteria (usually a female) were invited to participate between August and October 2011. Children aged out of the cohort when they reached 11 years of age. Participants were followed through June 2016; visits after December 31, 2014 from Tororo were excluded from this analysis because transmission changed dramatically at this site after intensive indoor residual spraying campaigns were started. Analytic follow-up time was a median of 55 months in Jinja, 57 months in Kanungu, and 39 months in Tororo. Further detail on the cohort is available from Kamya et al(46).

Clinical data were obtained via both active and passive follow-up. All participants visited the clinic quarterly to obtain thick blood smears. In addition, caregivers were asked to bring their children to study clinics to receive care for any illness free of charge. Thick blood smears were performed on all children who reported fever in the previous 24 hours or who were febrile (>38.0°C) at the sick visit. Parasitemia was determined based on microscopy and parasite density was calculated as previously described(23). Those with symptomatic malaria were treated with the first line treatment in Uganda, artemether-lumefantrine. Those with complicated or recurrent malaria (occurring within 14 days of last therapy) were treated with quinine(23).

Entomologic data were collected monthly at all study households. Mosquitoes were collected using miniature CDC light traps and tested for sporozoites using an ELISA technique, as previously described(47). For each household an annual entomological inoculation rate (EIR) was calculated as the product of the of the yearly household human biting rate (geometric mean of female Anopheles mosquitoes caught in a household per day) and the site sporozoite rate (average proportion of mosquitos that tested positive for *Plasmodium falciparum* in each site), as previously reported(23).

HLA and KIR Genotyping

HLA genotyping was performed using a targeted next generation sequencing (NGS) method. Briefly, locus-specific primers were used to amplify a total of 23 polymorphic exons of HLA-A, B, C (exons 1 to 4), DPA1 (exon 2), DPB1 (exons 2, 3), DQA1 (exon 2), DQB1 (exons 2, 3), DRB1 (exons 2, 3), and DRB3, 4, 5 (exon 2) genes with Fluidigm Access Array (Fluidigm

Singapore PTE Ltd, Singapore). The 23 Fluidigm PCR amplicons were pooled and subjected to sequencing on an illumina MiSeq sequencer (Illumina, San Diego, CA). HLA alleles and genotypes were called using the Omixon HLA Explore (beta version) software (Omixon, Budapest, Hungary).

KIR genotyping for the presence or absence of each KIR gene was conducted by PCR with sequence-specific priming (PCR-SSP) as described previously (48), with some modifications. Each PCR was conducted in a volume of 5 ul using 5 ng genomic DNA and SYBR Green PCR Master Mix with Platinum Taq (Invitrogen). Presence and absence of specific PCR products was detected by melting curve analysis on the 7900 Real-Time PCR System (Applied Biosystems).

HLA-C Expression Levels

HLA-C expression levels were imputed using estimates based on previously published quantitative measurements of HLA-C allotypes (38).

Statistics

We analyzed the association of KIR and their HLA ligands with five different outcomes related to malaria immunity:

1. Parasite prevalence: Prevalence of at least one symptomatic or asymptomatic parasite positive visit per quarter.

2. Annual malaria incidence rate: Number of symptomatic malaria episodes per person-year.

3. Parasite density: Log parasite density measured during visit (in analyses, stratified by two visit types: routine quarterly parasite-positive visits and symptomatic malaria visits).

4. Probability of symptoms if infected: Whether a participant was febrile if they were parasitemic. (Episodes of asymptomatic parasitemia where fever developed within 7 days and repeat episodes of febrile parasitemia within 7 days of initial episode were excluded so that each malarial episode was only counted once.)

5. Temperature at parasitemic visits: Objective temperature at parasitemic visits, conditional on parasite density.

First, we assessed the effect of each KIR individually on these outcomes. Next, we explored KIR-HLA compound genotypes as follows. HLA ligand group definitions are in Supplemental Table 6. KIR2DL1, which binds HLA-C2, was present in nearly all subjects (98.6%). KIR2DL2 and KIR2DL3 segregate as alleles of the same locus and have the same HLA ligand, HLA-C1; virtually everyone in this sample has KIR2DL2 and/or KIR2DL3 (99.3%). We examined the effect of having at least one copy of HLA-C2 among those with KIR2DL1 and of having at least one copy of HLA-C1 among those with KIR2DL2 and/or KIR2DL3. Building on this, we investigated HLA-C1/C2 zygosity in the entire sample to determine the effect of multiple copies of each ligand. We then assessed the effect of a joint variable: no HLA-C1 ligand (i.e. HLA-C2 homozygous), HLA-C1 with KIR2DL2 only, HLA-C1 with KIR2DL2 and KIR2DL3, or HLA-C1 with KIR2DL3 only. We repeated this analysis among those with no KIR2DS2 (for the outcome of parasite prevalence only). Another inhibitory KIR, KIR3DL1, was also nearly ubiquitous in the sample (98.7%). We again considered the effect of its ligand, HLA-Bw4, among those with the receptor. Given that both HLA-C2 and Bw4 affected parasite prevalence in

the same direction, we assessed the combined genotype of HLA-C2 and HLA-Bw4 (neither

HLA-C2 nor HLA-Bw4, only HLA-C2, only HLA-Bw4, or both HLA-C2 and HLA-Bw4).

Finally, we looked at the level of HLA-C expression (normalized as a z-score).

To estimate these effects, we used multi-level models with random effects at the individual- and

household-levels. We used logistic regression for parasite prevalence and probability of

symptoms if infected. We used Poisson models for malaria incidence. We used linear models for

log parasite density, as well as temperature. All models were adjusted for site, household log

entomological inoculation rate, sex, age (continuous linear term), and age-group (child vs. adult).

Models for temperature also controlled for log parasite density at that visit.

In summary, the models followed this general form (an example model for parasite prevalence

shown):

Parasite prevalence$_{ijk}$ = KIR-HLA compound genotype$_{ij}$ +Site$_j$ + Log(aEIR$_j$) +Sex$_i$ + Age$_{ijk}$ +

Child$_{ij}$ + Age*Child$_{ijk}$ + u$_i$ + y$_j$

where i indicates individuals, j indicates households, and k indcates specific visits. For example,

age$_{ijk}$ denotes the age of child i from household j during visit k. As aEIRj represents the average

annual EIR recorded for household j (time-invariant), we assume relatively stable transmission

intensity over the course of study follow-up.

We used Monte Carlo permutation tests to calculate exact p-values. We permuted exposure

variables 10,000 times and calculated the two-sided p-value as the number of permutations that

yielded coefficients greater than or equal to the absolute value of the observed coefficient divided by the number of models that converged (>99%) using the Stata ritest package version 1.1.4(49). For each outcome, we controlled for multiple testing separately using the false discovery rate (FDR) approach with the Stata qqvalue package(50). All analysis was done in Stata 15.1 (StataCorp, College Station, TX).

Finally, we performed the following sensitivity analyses for all models with the outcome of parasite prevalence: stratified by site, among children only, and among sickle cell wild type. We also estimated models using data from a more sensitive assay to detect parasites (loop-mediated isothermal amplification, LAMP), that was performed on microscopy negative samples for children. Children were considered parasitemic if they were positive either by microscopy or LAMP. Controlling for ethnicity (Bantu/non-Bantu) based on primary language spoken did not improve model fit as compared to controlling for site since these two variables were collinear.

Author Contributions

JCD, PCC, IRB and MEF designed experimental questions. IRB and JCD created statistical analysis plan and JCD performed all statistical analyses. PCC, MEF and JCD prepared original manuscript. GD, MK, EA and JR generated the clinical data set. MM and MC performed KIR and HLA genotyping. GN and MV validated statistical analyses. All authors contributed to review and editing of manuscript.

Acknowledgments

We are grateful to all the parents and guardians for kindly giving their consent, and to the study participants for their cooperation. We thank all the members of the study team for their tireless effort and excellent work. We thank Noam Teyssier for generously sharing his computing expertise and time. Support for this work was provided by the National Institute of Allergy and Infectious Diseases (R01AI093615 and K24AI113002 to M.E.F., U19AI089674 to M.E.F., G.D. and M.K) and Henry Wheeler Center for Emerging and Neglected Diseases (to P.C.C.). In addition, this project has been funded in part with federal funds from the Frederick National Laboratory for Cancer Research, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. This Research was supported in part by the Intramural Research Program of the NIH, Frederick National Lab, Center for Cancer Research.

Tables and Figures

Table 1. Characteristics of study population

	Jinja	Kanungu	Tororo
Households (N)	**97**	**100**	**95**
Median household EIR (range)	2.1 (1.5-22.0)	6.3 (3.0-44.5)	67.6 (11.5-588.4)
Adults (N)	**89**	**78**	**66**
Median incidence of symptomatic malaria episodes ppy (range)	0.0 (0.0-2.0)	0.2 (0.0-3.7)	0.0 (0.0-3.0)
Parasite prevalence (% quarters parasite+)	4.9%	12.8%	12.0%
Children (N)	**187**	**267**	**203**
Median age at enrollment, years (range)	4.4 (0.5-10.0)	4.7 (0.5-9.9)	5.1 (0.6-10.0)
Median incidence of symptomatic malaria episodes ppy (range)	0.2 (0.0-5.1)	1.2 (0.0-8.1)	2.1 (0.0-8.8)
Parasite prevalence (% quarters parasite +, range)	12.8%	36.4%	64.2%
Median follow up time, months (range)*	55.1 (2.3-58.6)	56.7 (0.0-58.3)	39.0 (1.8-40.3)
Sickle cell, n(%)			
AA	201 (72.8%)	323 (93.6%)	195 (72.5%)
AS	72 (26.1%)	22 (6.4%)	70 (26.0%)
SS	0 (0.0%)	0 (0.0%)	2 (0.7%)
No result	3 (1.1%)	0 (0.0%)	2 (0.7%)

*Note: 3 people in the sample had only one visit; Tororo visits after December 31, 2014 were excluded because transmission changed dramatically at this site after intensive indoor residual spraying campaigns were started.

Table 2. KIR and Ligand Prevalence

KIR and HLA prevalence	N=890
KIR	%
KIR2DL1†	98.6
KIR2DL2	54.7
KIR2DL3‡	84.8
KIR2DL4	99.7
KIR2DL5	57.9
KIR2DP1	98.1
KIR2DS1	23.5
KIR2DS2	49.0
KIR2DS3	23.0
KIR2DS4	68.3
KIR2DS5	42.6
KIR3DL1	98.7
KIR3DL2	99.6
KIR3DS1	13.0
HLA	%
C1/C2 ligand group zygosity*	
C1/C1	19.5
C1/C2	53.1
C2/C2	27.4
Bw4 ligand group (at least one copy)	74.8

Note: Reduced Ns due to failed amplification or lack of
DNA.

†N=888

‡N=883

*N=889

Table 3. Effect of HLA-C zygosity on parasite prevalence

C1/C2 zygosity[†]	OR	P-value	Empirical p-value	Empirical FDR q-value
C1/C1	Ref			
C1/C2	1.26	0.045	0.036	0.111
C2/C2	1.54	0.001	0.001	0.008

[†]N=889

Table 4. Effect of KIR2DL2/3 on parasite prevalence

	OR	P-value	Empirical p-value	Empirical FDR q-value
2DL2/3[†]				
no C1	1.24	0.061	0.045	0.115
C1 + 2DL2 only	1.03	0.845	0.837	0.837
C1 + 2DL2/2DL3	0.93	0.543	0.510	0.640
C1 + 2DL3 only	Ref			
2DL2/3 among those without 2DS2[‡]				
no C1	1.19	0.199	0.170	0.351
C1 + 2DL2 only or 2DL2/2DL3	1.60	0.024	0.016	0.056
C1 + 2DL3 only	Ref			

[†]N=882

[‡]N=453

References

1. Middleton D, Gonzelez F. The extensive polymorphism of KIR genes. *Immunology* 2010;129(1):8–19.

2. Andersson S, Fauriat C, Malmberg J-A, Ljunggren H-G, Malmberg K-J. KIR acquisition probabilities are independent of self-HLA class I ligands and increase with cellular KIR expression. *Blood* 2009;114(1):95–104.

3. Khakoo SI et al. HLA and NK Cell Inhibitory Receptor Genes in Resolving Hepatitis C Virus Infection. *Science* 2004;305(5685):872–874.

4. Mori M et al. Impact of HLA allele-KIR pairs on HIV clinical outcome in South Africa [Internet]. *J Infect Dis* doi:10.1093/infdis/jiy692

5. Bona DD et al. KIR2DL3 and the KIR ligand groups HLA-A-Bw4 and HLA-C2 predict the outcome of hepatitis B virus infection. *Journal of Viral Hepatitis* 2017;24(9):768–775.

6. World Health Organization. *World Malaria Report 2017*. Geneva, Switzerland: World Health Organization; 2018:

7. Kariuki SN, Williams TN. Human genetics and malaria resistance [Internet]. *Hum Genet* [published online ahead of print: March 4, 2020]; doi:10.1007/s00439-020-02142-6

8. Band G et al. Insights into malaria susceptibility using genome-wide data on 17,000 individuals from Africa, Asia and Oceania. *Nature Communications* 2019;10(1):1–19.

9. Hirayasu K et al. Significant Association of KIR2DL3-HLA-C1 Combination with Cerebral Malaria and Implications for Co-evolution of KIR and HLA. *PLOS Pathogens* 2012;8(3):e1002565.

10. Lourembam SD, Sawian CE, Baruah S. Differential association of KIR gene loci to risk of malaria in ethnic groups of Assam, Northeast India. *Infection, Genetics and Evolution* 2011;11(8):1921–1928.

11. Tran TM et al. An intensive longitudinal cohort study of Malian children and adults reveals no evidence of acquired immunity to Plasmodium falciparum infection. *Clin. Infect. Dis.* 2013;57(1):40–47.

12. Hansen SG et al. Cytomegalovirus vectors expressing Plasmodium knowlesi antigens induce immune responses that delay parasitemia upon sporozoite challenge. *PLOS ONE* 2019;14(1):e0210252.

13. Lyke KE et al. Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. *PNAS* 2017;114(10):2711–2716.

14. Hafalla JCR, Cockburn IA, Zavala F. Protective and pathogenic roles of CD8+ T cells during malaria infection. *Parasite Immunology* 2006;28(1–2):15–24.

15. Lefebvre MN, Harty JT. You Shall Not Pass: Memory CD8 T Cells in Liver-Stage Malaria [Internet]. *Trends in Parasitology* [published online ahead of print: December 13, 2019]; doi:10.1016/j.pt.2019.11.004

16. Hart GT et al. Antibody-dependent NK cell control of Plasmodium falciparum infection. *The Journal of Immunology* 2017;198(1 Supplement):68.19-68.19.

17. Hart GT et al. Adaptive NK cells in people exposed to Plasmodium falciparum correlate with protection from malaria. *Journal of Experimental Medicine* 2019;jem.20181681.

18. Arora G et al. NK cells inhibit Plasmodium falciparum growth in red blood cells via antibody-dependent cellular cytotoxicity. *eLife Sciences* 2018;7:e36806.

19. Jagannathan P et al. Loss and dysfunction of Vδ2$^+$ γδ T cells are associated with clinical tolerance to malaria. *Sci Transl Med* 2014;6(251):251ra117.

20. Farrington LA et al. Frequent Malaria Drives Progressive Vδ2 T-Cell Loss, Dysfunction, and CD16 Up-regulation During Early Childhood. *J Infect Dis* 2016;213(9):1483–1490.

21. Mamedov MR et al. A Macrophage Colony-Stimulating Factor-Producing γδ T Cell Subset Prevents Malarial Parasitemic Recurrence [Internet]. *Immunity* 2018;0(0). doi:10.1016/j.immuni.2018.01.009

22. Zaidi I et al. γδ T Cells Are Required for the Induction of Sterile Immunity during Irradiated Sporozoite Vaccinations. *The Journal of Immunology* 2017;ji1700314.

23. Rodriguez-Barraquer I et al. Quantification of anti-parasite and anti-disease immunity to malaria as a function of age and exposure [Internet]. *eLife* 2018; doi:10.7554/eLife.35832

24. Nakimuli A et al. Killer cell immunoglobulin-like receptor (KIR) genes and their HLA-C ligands in a Ugandan population. *Immunogenetics* 2013;65(11):765–775.

25. Biassoni R et al. Amino acid substitutions can influence the natural killer (NK)-mediated recognition of HLA-C molecules. Role of serine-77 and lysine-80 in the target cell protection from lysis mediated by group 2 or group 1 NK clones.. *J Exp Med* 1995;182(2):605–609.

26. Moesta AK et al. Synergistic Polymorphism at Two Positions Distal to the Ligand-Binding Site Makes KIR2DL2 a Stronger Receptor for HLA-C Than KIR2DL3. *The Journal of Immunology* 2008;180(6):3969–3979.

27. Winter CC, Gumperz JE, Parham P, Long EO, Wagtmann N. Direct Binding and Functional Transfer of NK Cell Inhibitory Receptors Reveal Novel Patterns of HLA-C Allotype Recognition. *The Journal of Immunology* 1998;161(2):571–577.

28. Carrington M et al. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. *The Journal of Experimental Medicine* 2005;201(7):1069–1075.

29. Moesta AK, Parham P. Diverse functionality among human NK cell receptors for the C1 epitope of HLA-C: KIR2DS2, KIR2DL2, and KIR2DL3 [Internet]. *Front. Immunol.* 2012;3. doi:10.3389/fimmu.2012.00336

30. Naiyer MM et al. KIR2DS2 recognizes conserved peptides derived from viral helicases in the context of HLA-C. *Science Immunology* 2017;2(15):eaal5296.

31. Grau GE et al. Monoclonal antibody against interferon gamma can prevent experimental cerebral malaria and its associated overproduction of tumor necrosis factor. *PNAS* 1989;86(14):5572–5574.

32. Hansen DS, Bernard NJ, Nie CQ, Schofield L. NK Cells Stimulate Recruitment of CXCR3+ T Cells to the Brain during Plasmodium berghei-Mediated Cerebral Malaria. *The Journal of Immunology* 2007;178(9):5779–5788.

33. Gumperz JE, Litwin V, Phillips JH, Lanier LL, Parham P. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor.. *J Exp Med* 1995;181(3):1133–1144.

34. Marco MD et al. Unveiling the Peptide Motifs of HLA-C and HLA-G from Naturally Presented Peptides and Generation of Binding Prediction Matrices. *The Journal of Immunology* 2017;199(8):2639–2651.

35. Apps R et al. Relative Expression Levels of the HLA Class-I Proteins in Normal and HIV-Infected Cells. *The Journal of Immunology* 2015;194(8):3594–3600.

36. Thomas R et al. HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C. *Nat Genet* 2009;41(12):1290–1294.

37. Corrah TW et al. Reappraisal of the Relationship between the HIV-1-Protective Single-Nucleotide Polymorphism 35 Kilobases Upstream of the HLA-C Gene and Surface HLA-C Expression. *J Virol* 2011;85(7):3367–3374.

38. Apps R et al. Influence of HLA-C expression level on HIV control. *Science* 2013;340(6128):87–91.

39. Mota MM et al. Migration of Plasmodium Sporozoites Through Cells Before Infection. *Science* 2001;291(5501):141–144.

40. Sturm A et al. Manipulation of Host Hepatocytes by the Malaria Parasite for Delivery into Liver Sinusoids. *Science* 2006;313(5791):1287–1290.

41. Crutcher JM, Hoffman SL. Malaria [Internet]. In: Baron S ed. *Medical Microbiology*. Galveston (TX): University of Texas Medical Branch at Galveston; 1996:

42. Moras M, Lefevre SD, Ostuni MA. From Erythroblasts to Mature Red Blood Cells: Organelle Clearance in Mammals [Internet]. *Front. Physiol.* 2017;8. doi:10.3389/fphys.2017.01076

43. Kim S et al. HLA alleles determine differences in human natural killer cell responsiveness and potency. *Proc Natl Acad Sci U S A* 2008;105(8):3053–3058.

44. Parsons MS, Zipperlen K, Gallant M, Grant M. Killer cell immunoglobulin-like receptor 3DL1 licenses CD16-mediated effector functions of natural killer cells. *Journal of Leukocyte Biology* 2010;88(5):905–912.

45. Lisovsky I et al. Differential contribution of education through KIR2DL1, KIR2DL3, and KIR3DL1 to antibody-dependent (AD) NK cell activation and ADCC [Internet]. *Journal of Leukocyte Biology* 0(0). doi:10.1002/JLB.4A0617-242RRR

46. Kamya MR et al. Malaria Transmission, Infection, and Disease at Three Sites with Varied Transmission Intensity in Uganda: Implications for Malaria Control. *Am J Trop Med Hyg* 2015;92(5):903–912.

47. Kilama M et al. Estimating the annual entomological inoculation rate for Plasmodium falciparum transmitted by Anopheles gambiae s.l. using three sampling methods in three sites in Uganda. *Malaria Journal* 2014;13(1):111.

48. Martin MP, Carrington M. KIR locus polymorphisms: genotyping and disease association analysis. *Methods Mol. Biol.* 2008;415:49–64.

49. Heß S. Randomization Inference with Stata: A Guide and Software: [Internet]. *The Stata Journal* [published online ahead of print: September 1, 2017]; doi:10.1177/1536867X1701700306

50. Newson RB. Frequentist Q-values for Multiple-test Procedures. *The Stata Journal* 2010;10(4):568–584.